DSM-5 - Overview of disorders by category

In the DSM-5 (and DSM-5-TR), Intellectual Developmental Disorder (formerly “mental retardation”) is defined as a neurodevelopmental disorder of onset before the age of 18, characterized by both significant impairments in intellectual functioning (e.g., IQ ≤ 70) and impairments in adaptive behavior across the conceptual, social, and practical domains of daily life.. These limitations are lifelong and originate in childhood, with the severity (mild, moderate, severe, profound) classified based on IQ scores combined with observations of daily functioning..

1. Definition and diagnostic criteria

1. Intellectual functioning: Based on standardized intelligence tests (IQ ≲ 70–75, approximately two standard deviations below the mean) .

2. Adaptive behavior: Deficiencies in at least one of the three domains:

• Conceptual skills (language, reading, mathematics)
• Social skills (empathy, social judgment)
• Practical skills (self-care, work, safety)

Development period: The disorder manifests before adulthood (before the age of 18), revealing a discrepancy between peers..

2. State of affairs of psychedelic research in Intellectual Developmental Disorder

There are no randomized clinical trials yet those psychedelic therapies – such as MDMA therapy or psilocybin-AT – evaluate specifically in people with an Intellectual Developmental Disorder.
Research into broader inclusion of persons with disabilities indicates that patients with physical or sensory impairments are often excluded from psy-trial protocols; similar exclusion almost certainly applies to people with cognitive impairments, which explains the absence of data..
This means that there no clinical evidence are for the safety, tolerability, or effectiveness of psychedelic substances specifically within this target group.

3. Theoretical mechanisms for potential application

Although direct data are lacking, preclinical and translation studies suggest that psychedelics may promote neuroplasticity and learning ability, which could be relevant in cognitive impairments:

• Neuroplasticity & BDNF activation: Classic psychedelics such as psilocybin induce a period of accelerated neural growth and enhanced LTP (long-term potentiation), with increased expression of BDNF-related genes in animal models and via direct binding to TrkB receptors for BDNF.
• Opening critical learning periods: According to recent reviews, MDMA can open a window for intensive learning and emotional processing by reducing activity in fear-anxiety circuits and increasing empathy, which can facilitate behavioral change..
• Accelerated plasticity parallel to clinical effects: Systematic reviews show that molecular and cellular adaptations underlie the long-lasting therapeutic effects of psychedelics, which could theoretically lead to improved cognitive flexibility..

4. Possible approaches and precautions

• Psilocybin microdosing: Very low doses (microdoses) can theoretically lead to subtle increases in attention and learning ability without a full psychedelic trip, but controlled human studies are still lacking..
• MDMA-assisted group interventions: An empathogenic effect can support social training or communication training, provided it takes place in a low-stimulus environment and under intensive monitoring. .
• Strict inclusion criteria: Every future trial must use very low starting doses, and patients must be free of contraindications (such as cardiovascular instability or active psychosis)., and provide intensive pre- and post-session guidance through a multidisciplinary team (psychiatrist, developmental psychologist, expert by experience).
• Focus on adaptive skills: Goals could be aimed at concrete improvement of daily skills (task completion, social interaction) rather than merely symptomatic relief.

Conclusion: Although Intellectual Developmental Disorder is clearly defined in DSM-5 as a disorder with impairments in intellectual and adaptive functioning, there is no direct investigation yet towards psychedelic therapies in this population. Mechanistically, the literature on neuroplasticity and empathogenic learning offers hope for possible interventions, but clinical trials will need to be designed very carefully—with low-stimulus environments, low doses, multidisciplinary supervision, and strict safety protocols—before statements can be made regarding effectiveness and safety in clients with an Intellectual Developmental Disorder.

Language disorders, as defined in the DSM-5, are neurodevelopmental disorders that manifest as significant impairments in understanding and/or producing language. Traditional treatments include speech therapy and other language-focused interventions. Recently, however, interest has emerged in the potential role of psychedelics in treating various neurological and psychological conditions. This article examines the current state of affairs regarding the use of psychedelics in language disorders.

---

Current Research into Psychedelics and Language

Although there is limited research into the direct effect of psychedelics on language disorders, there are a few studies that may be relevant:

Stuttering and Psychedelics: A preliminary self-report study suggests that classic psychedelics may have positive effects on stuttering, which is a specific form of language disorder.

Neuroplasticity: Research in mice shows that psychedelics can reopen critical periods for social and language-related learning processes, suggesting that these substances can temporarily put the brain in a more learnable state.

Language production: Studies have shown that psychedelics can influence the structure and semantics of language, which may have implications for therapies aimed at language production.

---

Possible Mechanisms

The hypothesis is that psychedelics promote neuroplasticity, allowing the brain to form new connections. This could aid in retraining language skills in individuals with language disorders. Furthermore, psychedelics can modulate activity in brain regions involved in language processing, which could offer therapeutic benefits.

---

Caution and Ethical Considerations

It is important to emphasize that the use of psychedelics for language disorders is still in its infancy. There are ethical and safety concerns, particularly regarding children and adolescents, due to the potential risks to the developing brain. Additionally, psychedelics are illegal in many countries.

---

Conclusion

Although there are promising indications that psychedelics may play a role in treating language disorders, more rigorous research is needed to determine their effectiveness and safety. Until then, traditional treatments, such as speech therapy, remain the standard of care for language disorders.